Nivolumab

Introduction Overview

Generic Name

nivolumab

Brand Name

Opdivo

Dosage Form

Injection for intravenous infusion (40 mg/4 mL, 100 mg/10 mL, 120 mg/12 mL, 240 mg/24 mL)

Drug Class

Anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)

Pharmacokinetics

Absorption:
Nivolumab is administered exclusively via the intravenous (IV) route, which allows for complete bioavailability and immediate systemic distribution. As a monoclonal antibody, it is not absorbed through oral or mucosal membranes and requires infusion directly into the bloodstream. Because of its protein structure, nivolumab is not subject to first-pass metabolism or degradation in the gastrointestinal tract, thereby circumventing the variability inherent to oral drug absorption.

Distribution:
Following IV administration, nivolumab exhibits a volume of distribution approximating plasma volume, consistent with its large molecular size and limited ability to penetrate tissues extensively. It preferentially distributes within the vascular and extracellular spaces. The monoclonal antibody does not significantly cross the blood-brain barrier under normal physiologic conditions but may accumulate in tumors expressing its target. Binding is highly specific to PD-1 receptors on T cells, which modulate immune response. Protein binding is not classically measured for nivolumab due to its antibody nature.

Metabolism:
Nivolumab, like other therapeutic monoclonal antibodies, undergoes catabolic degradation via proteolytic enzymes throughout the reticuloendothelial system and endothelial cells. This metabolism breaks the antibody into small peptides and amino acids, which are recycled or eliminated. The drug is not metabolized by cytochrome P450 enzymes, reducing potential drug-drug interactions involving this pathway. The metabolic rate may be influenced by factors affecting the body's protein handling capacity, such as disease state and immune activation.

Elimination:
Elimination of nivolumab occurs primarily through nonspecific catabolism rather than renal or hepatic clearance mechanisms typically seen with small molecules. Its half-life is approximately 25 days, supporting dosing intervals ranging from every 2 to 4 weeks depending on the regimen. Clearance is influenced by target-mediated drug disposition, where binding to PD-1 receptors may alter pharmacokinetics in certain conditions. The long half-life facilitates relatively sustained receptor blockade and immunomodulatory effects, but it also necessitates vigilance for delayed onset or prolonged immune-related adverse effects.

Overall, nivolumab displays pharmacokinetic properties characteristic of immune checkpoint inhibitor monoclonal antibodies, with IV administration ensuring complete delivery, limited tissue distribution mainly confined to extracellular fluid, catabolic metabolism to peptides, and prolonged elimination half-life supporting intermittent dosing schedules.

Dosage Forms

Available Dosage Forms:
Nivolumab is available as a sterile, preservative-free injection solution for intravenous infusion in single-dose vials with the following strengths:
- 40 mg/4 mL (10 mg/mL)
- 100 mg/10 mL (10 mg/mL)
- 120 mg/12 mL (10 mg/mL)
- 240 mg/24 mL (10 mg/mL)

Dosages for Adults and Adolescents:
Dosing schedules are variable and tailored according to cancer type, therapy combination, and patient characteristics. Generally, nivolumab is administered as a 30-minute IV infusion every 2 to 4 weeks. Specific examples include:
- Melanoma: 240 mg every 2 weeks or 480 mg every 4 weeks; adjuvant treatment doses may differ.
- Non-small cell lung cancer (NSCLC): 240 mg every 2 weeks or 480 mg every 4 weeks, often combined with ipilimumab or chemotherapy.
- Renal cell carcinoma: 240 mg every 2 weeks or 480 mg every 4 weeks; can be combined with cabozantinib or ipilimumab.
- Classical Hodgkin lymphoma: 240 mg every 2 weeks.
- Pediatric patients aged 12 years and older: dosing mirrors adult regimens, especially for melanoma and colorectal cancer.

Specific Patient Populations:
- Pediatric Use: Approved for melanoma and colorectal cancer patients 12 years and older with dose adjustments based on body weight and surface area in clinical settings.
- Renal or Hepatic Impairment: No dose adjustment required; however, patients should be closely monitored for adverse effects.
- Elderly Patients: Standard dosing applies, but increased monitoring for adverse events is advised due to comorbidities.
- For combination therapies (e.g., with ipilimumab), dosing frequency and amount may be modified to optimize efficacy and manage toxicity.

Clinical guidelines recommend dosing adjustments or delays based on toxicity severity, particularly immune-mediated adverse reactions. All dosing should be administered under medical supervision in specialized oncology settings.

Mechanism Of Action

Nivolumab is a fully human IgG4 monoclonal antibody that acts as an immune checkpoint inhibitor by targeting programmed death-1 (PD-1) receptors expressed on activated T lymphocytes. Under physiological conditions, PD-1 receptors bind to their ligands PD-L1 and PD-L2, which are often overexpressed on tumor cells and within the tumor microenvironment. This interaction downregulates T-cell activity by inducing inhibitory signals, effectively reducing the immune system's ability to recognize and attack cancer cells.

By binding selectively to the PD-1 receptor, nivolumab blocks its interaction with both PD-L1 and PD-L2 ligands, preventing the transmission of inhibitory signals. This blockade releases the immune checkpoint 'brake,' allowing T cells to regain their activity, proliferate, and mount sustained immune responses against tumor cells. This reactivation leads to enhanced cytotoxic T lymphocyte-mediated destruction of cancer cells, reducing tumor burden.

Nivolumab's mechanism impacts multiple cellular pathways involved in immune tolerance and evasion, including modulation of regulatory T cells and effector T-cell exhaustion reversal. Additionally, nivolumab indirectly influences the tumor microenvironment by facilitating greater infiltration of activated T cells and promoting an immunologically 'hot' tumor phenotype, which is more susceptible to immune-mediated attack.

Clinical studies have demonstrated that nivolumab’s mechanism of action translates into significant and durable antitumor responses across various malignancies, including melanoma, NSCLC, renal cell carcinoma, and others. When combined with other immunotherapies, such as ipilimumab (a CTLA-4 inhibitor), the synergistic blockade of multiple immune checkpoints can further enhance antitumor immunity, albeit with increased risk of immune-related adverse events. Compared with other PD-1 inhibitors like pembrolizumab, nivolumab has a similar mechanism but may differ in treatment protocols or cancer indications based on clinical trial outcomes.

Pharmacological Actions

Immune checkpoint inhibition via PD-1 receptor blockade resulting in reactivation of T-cell-mediated immune response against tumor cells.
Enhancement of cytotoxic T lymphocyte activity, proliferation, and infiltration into tumor tissue.
Prevention of tumor-induced immune tolerance by disrupting PD-1/PD-L1/PD-L2 interactions.
Modulation of tumor microenvironment towards immunostimulatory phenotype.
Synergistic immunomodulation when combined with other checkpoint inhibitors like CTLA-4 antagonists (e.g., ipilimumab).
Induction of durable antitumor responses in multiple cancer types through immune-mediated mechanisms.
No direct cytotoxicity to tumor cells; activity is mediated entirely via immune system engagement.
Inhibition of T-cell exhaustion pathways leading to enhanced immune surveillance.
Alteration of cytokine secretion profiles favoring antitumor immunity.
Potential for immune-related adverse events due to generalized immune activation.

Therapeutic Or Clinical Uses

Treatment of unresectable or metastatic melanoma in adults and children aged 12 years and older, including adjuvant therapy for resected Stage IIB-IV melanoma.
Management of non-small cell lung cancer (NSCLC), including metastatic, recurrent, neoadjuvant, and first-line settings in combination with chemotherapy or ipilimumab.
Treatment of malignant pleural mesothelioma in adults with unresectable disease in combination with ipilimumab.
Therapy of intermediate and poor-risk advanced renal cell carcinoma in adults, including combinations with ipilimumab or cabozantinib.
Management of relapsed or refractory classical Hodgkin lymphoma in adults, especially post-autologous stem cell transplant.
Treatment of recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based therapy.
Adjuvant and first-line treatment for high-risk urothelial carcinoma, including unresectable or metastatic disease with cisplatin plus gemcitabine.
Therapy for unresectable/metastatic MSI-high or mismatch repair deficient colorectal cancer in adults and adolescents aged 12 years and older.
Treatment of hepatocellular carcinoma (HCC) either as first-line therapy with ipilimumab or after sorafenib failure.
Management of esophageal and gastroesophageal junction cancers with residual disease post-neoadjuvant chemoradiotherapy, and advanced/metastatic PD-L1 positive disease combined with chemotherapy or ipilimumab.
Treatment of advanced/metastatic gastric or gastroesophageal junction adenocarcinoma with PD-L1 positivity in combination with fluoropyrimidine and platinum-containing chemotherapy.

Side Or Adverse Effects

Nausea, vomiting, and abdominal pain.
Gastrointestinal disturbances including diarrhea and constipation.
Mouth sores and altered taste sensation.
Dermatological reactions such as rash, itching, redness, blistering, or peeling skin.
Immune-mediated hormonal dysfunctions including hypothyroidism and hyperthyroidism.
Hepatic adverse effects including elevated liver enzymes and hepatitis.
Neurological symptoms such as numbness, tingling, or burning sensations in extremities.
Constitutional symptoms including fever, body aches, fatigue, and weakness.
Respiratory symptoms including cough, shortness of breath, and upper respiratory infections.
Headache, dizziness, and occasional elevations in blood pressure.
Weight loss and decreased appetite.
Infusion-related reactions such as chest tightness, wheezing, facial flushing, swelling, and hives.
Serious immune-related adverse events involving lung inflammation (pneumonitis), colitis, nephritis, endocrinopathies, and skin toxicity.
Potential for severe allergic reactions or anaphylaxis.
Combination therapy with ipilimumab increases frequency and severity of above side effects including musculoskeletal pain.

Precautions

Careful assessment and monitoring in patients with pre-existing immune system disorders such as Crohn’s disease, ulcerative colitis, or lupus.
Caution in patients with prior organ transplantation due to risk of transplant rejection.
Avoidance or close monitoring in patients with liver impairment or prior hepatic disease.
Special vigilance for patients who have undergone or plan to undergo allogeneic stem cell transplantation due to risks of graft-versus-host disease.
Not indicated for use with thalidomide and dexamethasone in multiple myeloma outside controlled trials.
Pregnancy test advised before initiation; use effective contraception during treatment and for 5 months after discontinuation due to fetal harm risk.
Avoid breastfeeding during treatment and for 5 months post-therapy because of unknown passage into breast milk.
Gradual monitoring for early signs of immune-related adverse effects; prompt management with corticosteroids or immunosuppressants if needed.
Periodic laboratory tests including liver function, kidney function, thyroid function, and hematologic parameters are recommended.
Adjust or delay therapy in response to adverse immune-mediated toxicities.
Inform patients about symptoms of immune activation requiring immediate medical attention.
Avoid abrupt discontinuation without medical guidance to prevent rebound effects or loss of disease control.
Monitor cardiovascular and neurologic symptoms as immune-related toxicity may affect these systems.
Evaluate concomitant medications for potential interactions or additive immune effects.
Immunization status should be reviewed; live vaccines are contraindicated during treatment.

Warnings

Risk of severe and potentially fatal immune-mediated adverse reactions affecting lungs (pneumonitis), intestines (colitis), liver (hepatitis), endocrine glands, kidneys, skin, and other organs.
Potential for graft-versus-host disease in patients with prior allogeneic stem cell transplantation.
Infusion-related hypersensitivity reactions including anaphylaxis requiring immediate discontinuation and management.
Risk of transplant organ rejection; patients with prior organ transplants require close monitoring.
May cause fetal harm; contraindicated during pregnancy unless potential benefit justifies the risk.
Immune-related adverse events can occur at any time during or after treatment, sometimes weeks to months post-therapy.
Delayed onset of immune toxicities necessitates prolonged observation even after discontinuation.
Cancer treatment may need to be postponed or permanently discontinued due to severity of side effects.
Concomitant use with other immunosuppressive agents may mask toxicity or impact efficacy.
Patients should be educated to report symptoms such as new cough, severe diarrhea, abdominal pain, skin rash, jaundice, or endocrine symptoms immediately.
Nivolumab is not recommended for patients with compromised immune systems from conditions like HIV without specialist assessment.
Potential for severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis.
Increased risk of infections due to immune modulation.
Use caution in patients with pre-existing neurologic disorders such as myasthenia gravis or Guillain-Barré syndrome.
Avoid abrupt corticosteroid withdrawal when managing side effects to prevent adrenal crisis.

Contraindication

Known hypersensitivity to nivolumab or any component of the formulation.
Concurrent use with thalidomide and dexamethasone in multiple myeloma outside clinical trials.
Use during pregnancy unless absolutely necessary due to teratogenic risk.
Active autoimmune diseases requiring systemic immunosuppression.
Patients with severe infusion-related hypersensitivity reactions to nivolumab.
Patients with uncontrolled infections or immunodeficiency states.
Severe liver impairment without specialist evaluation.
Use in combination with other immune checkpoint inhibitors beyond approved indications without proper clinical justification.
Severe psychiatric or neurologic disorders that may impair reporting of adverse effects or compliance.
Patients who have received prior treatment with immune checkpoint inhibitors with severe unresolved toxicities.
History of severe graft-versus-host disease post allogeneic stem cell transplantation.
Known active tuberculosis or other uncontrolled infections due to risk of exacerbation.
Certain cases of congestive heart failure or severe pulmonary disease requiring caution and specialist oversight.
Inability to comply with monitoring and management requirements for immune-related toxicities.
Use in patients with known hypersensitivity to components such as polysorbate 80 or sodium citrate.

Drug Interactions

No significant cytochrome P450-mediated interactions due to monoclonal antibody metabolism.
Potential interaction with other immunosuppressive agents that may alter immune response efficacy or toxicity profile.
Avoid concomitant administration with thalidomide and dexamethasone in multiple myeloma without clinical trial oversight.
Immunomodulating agents including corticosteroids may reduce effectiveness if used concomitantly for immune-related adverse events.
Concurrent chemotherapy or corticosteroids may affect nivolumab pharmacodynamics and toxicity.
Vaccinations with live attenuated vaccines are contraindicated due to altered immune responses.
Potential enhanced toxicity when combined with other immune checkpoint inhibitors such as ipilimumab, requiring dose adjustment and close monitoring.
No direct interactions with common medications such as antihypertensives, antidiabetics, or analgesics have been documented but clinical vigilance is advised.
Concomitant use with agents that depress bone marrow function may exacerbate hematologic toxicities.
Herbal or vitamin supplements lacking evidence on interaction; patients should inform providers of all supplements.
Drug interactions altering renal or hepatic function may indirectly affect nivolumab clearance though no direct metabolism involvement.
Concomitant medications influencing T-cell function may modulate nivolumab activity.
Avoid strong immunosuppressants unless indicated for managing immune-related side effects.
Monitoring for additive immune suppression or activation is critical when multiple immune-modulating drugs are used concurrently.
Interactions may alter adverse event profile requiring dose modifications or treatment delays.

Preparations Of The Drug

Nivolumab is provided as a sterile, preservative-free, clear to slightly opalescent, colorless to pale yellow solution for intravenous infusion.
Available in single-use vials at concentrations of 10 mg/mL with total volumes of 40 mL, 100 mL, 120 mL, and 240 mL corresponding to 40 mg, 100 mg, 120 mg, and 240 mg doses respectively.
Formulated with inactive ingredients including mannitol, pentetic acid, polysorbate 80, sodium chloride, sodium citrate dihydrate, and water for injection; pH adjusted with hydrochloric acid and/or sodium hydroxide as needed.
Stored refrigerated at 2°C to 8°C (36°F to 46°F), protected from light in original packaging until use.
Must not be frozen or shaken vigorously to maintain molecular integrity and prevent aggregation.
Before administration, nivolumab vials are visually inspected for particulate matter and discoloration; vials exhibiting contamination or cloudiness should be discarded.
Prepared under aseptic conditions and diluted in compatible intravenous fluids such as 0.9% sodium chloride injection following institutional protocols.
Administered as a controlled IV infusion over approximately 30 minutes under medical supervision with monitoring for infusion reactions.
Single-dose vials do not contain preservatives, and any unused portion must be discarded after vial puncture.
Compatibility with infusion lines and filters should be confirmed to avoid adsorption or degradation.
Batch records and lot identification maintained for traceability during dispensing and administration.
Patient-specific dose preparation is required due to weight-based or fixed dosing regimens.
Pharmacy staff should adhere to handling guidelines for biologics to maintain drug efficacy and safety.
Disposal of unused drug and materials should follow biohazard and pharmaceutical waste regulations.
Storage and handling recommendations aim to preserve nivolumab’s stability and reduce the risk of adverse events due to product degradation.